Intersect ENT Inc (NASDAQ:XENT) CFO Jeryl L. Hilleman sold 12,833 shares of the company’s stock in a transaction dated Monday, October 8th. The shares were sold at an average price of $27.99, for a total transaction of $359,195.67. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Jeryl L. Hilleman also recently made the following trade(s):
- On Friday, September 14th, Jeryl L. Hilleman sold 12,833 shares of Intersect ENT stock. The shares were sold at an average price of $28.92, for a total transaction of $371,130.36.
Shares of XENT stock opened at $30.51 on Friday. The stock has a market capitalization of $875.57 million, a price-to-earnings ratio of -54.48 and a beta of 0.56. Intersect ENT Inc has a one year low of $25.15 and a one year high of $42.95.
Intersect ENT (NASDAQ:XENT) last issued its earnings results on Wednesday, August 1st. The medical equipment provider reported ($0.14) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.03. The business had revenue of $26.30 million for the quarter, compared to the consensus estimate of $28.15 million. Intersect ENT had a negative net margin of 17.22% and a negative return on equity of 15.01%. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.08) EPS. On average, sell-side analysts anticipate that Intersect ENT Inc will post -0.86 earnings per share for the current fiscal year.
Several brokerages recently commented on XENT. BidaskClub upgraded shares of Intersect ENT from a “sell” rating to a “hold” rating in a report on Thursday. ValuEngine downgraded shares of Intersect ENT from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 16th. BTIG Research reiterated a “hold” rating on shares of Intersect ENT in a report on Thursday, August 2nd. Canaccord Genuity reiterated a “buy” rating on shares of Intersect ENT in a report on Wednesday, August 1st. Finally, Piper Jaffray Companies cut their price target on shares of Intersect ENT from $45.00 to $40.00 and set an “overweight” rating on the stock in a report on Wednesday, August 1st. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $40.33.
Hedge funds have recently modified their holdings of the business. SG Americas Securities LLC bought a new position in Intersect ENT in the 1st quarter worth about $132,000. Meeder Asset Management Inc. grew its stake in Intersect ENT by 565.6% in the 2nd quarter. Meeder Asset Management Inc. now owns 3,987 shares of the medical equipment provider’s stock worth $149,000 after acquiring an additional 3,388 shares in the last quarter. UBS Group AG grew its stake in Intersect ENT by 81.1% in the 1st quarter. UBS Group AG now owns 4,679 shares of the medical equipment provider’s stock worth $184,000 after acquiring an additional 2,096 shares in the last quarter. Aperio Group LLC bought a new position in Intersect ENT in the 1st quarter worth about $213,000. Finally, All Terrain Financial Advisors LLC bought a new position in Intersect ENT in the 1st quarter worth about $241,000. Institutional investors and hedge funds own 90.30% of the company’s stock.
Intersect ENT Company Profile
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.